Back to search

Article

COVID-19 prevention with alternate vaccine boosting frequencies for multiple-sclerosis patients undergoing therapy with beta-interferon, dimethyl fumarate, natalizumab, or teriflunomide

2024-09-22

Abstract excerpt

Multiple-sclerosis patients undergoing treatment with disease-modifying therapies exhibit diverse immune responses to COVID-19 vaccinations. However, guidance on how specific treatments influence infection risks and optimal vaccination schedules remains limited. This study integrates data on vaccine-induced and infection-derived antibody responses to predict cumulative probabilities of breakthrough infections in u...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f31fcdf9-d95d-5d3b-9d48-88c4ad5c7341
DOI
10.1101/2024.09.19.24313891
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
COVID-19 prevention with alternate vaccine boosting frequencies for multiple-sclerosis patients undergoing therapy with beta-interferon, dimethyl fumarate, natalizumab, or teriflunomideDOI 10.1101/2024.09.19.24313891
Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity
Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in EnglandSemantic proximity
Response to COVID-19 booster vaccinations in seronegative people with MSSemantic proximity
Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity
Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapySemantic proximity
COVID-19 vaccines and autoimmune disorders: A scoping review protocolSemantic proximity
Different HLA genotype pattern in patients with Multiple Sclerosis onset after COVID-19 vaccine.Semantic proximity
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and rheumatoid arthritis patientsSemantic proximity
Disease Modifying Therapies and COVID-19 Severity in Multiple SclerosisSemantic proximity
Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis.Semantic proximity
Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort studySemantic proximity
Select a neighboring publication to make it the new centre.